Nuclear medicine, as a leading technology for the diagnosis and treatment of malignant tumors, is attracting industry attention at an unprecedented rate. This medical weapon that integrates radioactive isotopes with nuclear technology showcases its unique advantages of precise targeting, efficient killing, low damage, and integrated diagnosis and treatment in major diseases such as cardiovascular and cerebrovascular diseases, cancer, etc., demonstrating its strength in the global arena, with increasingly widespread applications. In recent years, with domestic policy support and proactive company layouts, the nuclear medical industry has entered a golden development period. The upstream development of nuclear technology, midstream research and development of radiopharmaceuticals and nuclear diagnostic and treatment equipment, as well as downstream clinical applications, have led to vigorous development along the entire industry chain, attracting listed companies such as Yantai Dongcheng Biochemicals, Yunnan Baiyao Group, CGN Nuclear Technology Development, etc., with accelerated layouts in Zhejiang, Jiangsu, and other regions, while Sichuan has even proposed to build a world-class nuclear medical industry cluster. However, the development and promotion of the nuclear medical industry still face challenges.